Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totalling 2,900 shares, a decrease of 65.9% from the December 31st total of 8,500 shares. Based on an average daily volume of 300,500 shares, the short-interest ratio is currently 0.0 days.

Provectus Biopharmaceuticals Stock Up 2.2 %

Shares of Provectus Biopharmaceuticals stock traded up $0.00 on Tuesday, reaching $0.12. 40,450 shares of the company were exchanged, compared to its average volume of 212,674. Provectus Biopharmaceuticals has a fifty-two week low of $0.04 and a fifty-two week high of $0.22. The stock has a fifty day moving average price of $0.12 and a 200-day moving average price of $0.11.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.